Translator Disclaimer
10 June 2011 A Single Dose of an Inhibitor of Cyclooxygenase 2, Meloxicam, Administered Shortly after Irradiation Increases Survival of Lethally Irradiated Mice
Author Affiliations +
Abstract

This study extends earlier findings of the authors demonstrating that meloxicam, a selective inhibitor of cyclooxygenase 2, supports hematopoietic recovery in sublethally irradiated mice and is radioprotective when given before irradiation. We report here that when meloxicam was administered in a single dose 1 h after a lethal 9-Gy whole-body dose, an increased 30-day survival was achieved. Additional studies showed that administration of meloxicam 24 h after lethal irradiation is ineffective and its repeated administration deleterious. Possible mechanisms of the therapeutic effects of meloxicam administered early after irradiation are discussed.

by Radiation Research Society
M. Hofer, M. Pospíšil, L. Dušek, Z. Hoferová, and L. Weiterová "A Single Dose of an Inhibitor of Cyclooxygenase 2, Meloxicam, Administered Shortly after Irradiation Increases Survival of Lethally Irradiated Mice," Radiation Research 176(2), 269-272, (10 June 2011). https://doi.org/10.1667/RR2614.1
Received: 2 March 2011; Accepted: 1 April 2011; Published: 10 June 2011
JOURNAL ARTICLE
4 PAGES


SHARE
ARTICLE IMPACT
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top